US Edition
Nektar, Continuing Comeback, Says Eczema Drug’s Effects Hold up in Follow-up Study
Nektar's 52-week REZOLVE-AD trial showed up to 83% sustained EASI-75 response and favorable safety, supporting rezpegaldesleukin's advancement to Phase 3 studies.
- On Tuesday, February 10, 2026, Nektar Therapeutics announced positive 52-week REZOLVE-AD maintenance results and hosted a webcast to review topline data.
- The global REZOLVE-AD Phase 2b study enrolled 393 patients with moderate-to-severe atopic dermatitis across approximately 110 sites globally, using a 16-week induction and randomized 3:3:3:2.
- In the maintenance period, 24 μg/kg dosing maintained EASI-75 in 71% and 83% of responders and vIGA-AD 0/1 in 85% and 63%, with increased EASI-100 conversions and deeper responses at Week 52.
- Nektar and investigators said safety was consistent with induction, 72% TEAEs for rezpegaldesleukin, mostly mild injection-site reactions, supporting advancement to Phase 3 studies.
- With Fast Track designation, experts said rezpegaldesleukin, a first-in-class Treg biologic, shows potential for rapid development in atopic dermatitis.
22 Articles
22 Articles
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg monthly and quarterly dosing, respectively...
The Union Democrat
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the…
Biotech Stock Nektar Therapeutics (Nasdaq: NKTR) Makes Top Gainer List on News of REZOLVE-AD study
Nektar Therapeutics (Nasdaq: NKTR) surged onto the Nasdaq top gainers list after reporting positive Phase 2b results from its REZOLVE-AD study of rezpegaldesleukin in moderate-to-severe atopic dermatitis, demonstrating durable responses, improved disease control, and strong long-term efficacy through 52 weeks.
Coverage Details
Bias Distribution
- 92% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
